Rhythm Pharmaceuticals

Rhythm expands obesity portfolio with Phase II weight loss drug for $100m
Clinical Trials Arena
Fri, 01/5/24 - 11:21 am
Rhythm Pharmaceuticals
LG Chem
obesity
LB54640
Why Rhythm Pharmaceuticals Stock Is Rocketing Higher Today
Motley Fool
Tue, 08/2/22 - 11:26 pm
Rhythm Pharmaceuticals
earnings
Rhythm's Imcivree Scores FDA Approval in Bardet-Biedl Syndrome
BioSpace
Fri, 06/17/22 - 10:29 am
Rhythm Pharmaceuticals
Imcivree
Bardet-Biedl syndrome
FDA
Looking to win over some skeptical analysts, Rhythm beats the drum on interim data in PhII basket study for additional indications
Endpoints
Tue, 01/26/21 - 11:19 am
Rhythm Pharmaceuticals
clinical trials
setmelanotide
obesity
Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many
Endpoints
Tue, 12/22/20 - 10:54 am
Rhythm Pharmaceuticals
setmelanotide
obesity
clinical trials
FDA gives Rhythm the green light for setmelanotide, a drug aimed at reducing obesity in certain genetic disorders
Endpoints
Mon, 11/30/20 - 10:38 am
Rhythm Pharmaceuticals
setmelanotide
obesity
FDA
The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates
Yahoo/Benzinga
Sun, 11/22/20 - 11:53 pm
vaccines
COVID-19
Roche
ReVance
Moderna Therapeutics
FDA
Rhythm Pharmaceuticals
Liquidia
Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO
Xconomy
Tue, 03/31/20 - 10:07 pm
Rhythm Pharmaceuticals
FDA
setmelanotide
Rhythm Pharma CEO Gottesdeiner to Step Down After FDA Filing
Xconomy
Mon, 01/6/20 - 11:35 pm
Rhythm Pharmaceuticals
Keith Gottesdiener
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
Sun, 09/22/19 - 11:10 pm
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Rhythm’s genetic obesity drug hits primary endpoint in phase 3
Fierce Biotech
Wed, 08/7/19 - 10:43 am
Rhythm Pharmaceuticals
genetic obesity
clinical trials
setmelanotide
Building up its rare obesity pipeline, Rhythm Pharma to raise $150M
Endpoints
Tue, 06/19/18 - 10:53 am
Rhythm Pharmaceuticals
R&D
obesity
Successful IPO for Rhythm Pharmaceuticals: +52%
GoinPharma
Sun, 10/15/17 - 12:34 pm
IPOs
Rhythm Pharmaceuticals
Rhythm Pharma strikes a chord with oversubscribed $120M IPO
Fierce Biotech
Sat, 10/7/17 - 11:05 am
Rhythm Pharmaceuticals
IPOs
Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
Endpoints
Wed, 09/6/17 - 10:37 am
Rhythm Pharmaceuticals
IPOs
obesity
rare disease
Pfizer, OrbiMed back $40M Rhythm round for rare genetic disease R&D
Fierce Biotech
Sun, 08/16/15 - 10:30 am
Pfizer
OrbiMed
Rhythm Pharmaceuticals
Prader-Willi Syndrome
Two new biotech IPOs help set the stage for the fall parade
Fierce Biotech
Thu, 08/28/14 - 11:04 am
IPOs
Rhythm Pharmaceuticals
Dermira
Rhythm Pharmaceuticals lands $11M tranche to advance its treatment of GI disorders
bizjournals
Wed, 07/31/13 - 10:05 am
Rhythm Pharmaceuticals
gastroparesis
diabetes
obesity
Rise in obesity makes VCs hungry for startups
Reuters
Fri, 03/26/10 - 09:10 am
venture capital
obesity
Rhythm Pharmaceuticals
Elixir Medical